nodes	percent_of_prediction	percent_of_DWPC	metapath
Octreotide—MPO—Carboplatin—uterine cancer	0.435	1	CbGbCtD
Octreotide—SSTR4—female reproductive system—uterine cancer	0.00714	0.216	CbGeAlD
Octreotide—SSTR4—female gonad—uterine cancer	0.0065	0.196	CbGeAlD
Octreotide—MPO—artery—uterine cancer	0.00526	0.159	CbGeAlD
Octreotide—SSTR2—renal system—uterine cancer	0.00488	0.148	CbGeAlD
Octreotide—SSTR1—female reproductive system—uterine cancer	0.0046	0.139	CbGeAlD
Octreotide—MPO—epithelium—uterine cancer	0.00199	0.0603	CbGeAlD
Octreotide—MPO—renal system—uterine cancer	0.00185	0.0559	CbGeAlD
Octreotide—MPO—lymph node—uterine cancer	0.000867	0.0262	CbGeAlD
Octreotide—MPO—Vitamin B12 Metabolism—CCL2—uterine cancer	0.000589	0.015	CbGpPWpGaD
Octreotide—SSTR4—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000517	0.0132	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—MTHFR—uterine cancer	0.000487	0.0124	CbGpPWpGaD
Octreotide—MPO—Folate Metabolism—CCL2—uterine cancer	0.000479	0.0122	CbGpPWpGaD
Octreotide—SSTR4—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000408	0.0104	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000392	0.00999	CbGpPWpGaD
Octreotide—MPO—IL23-mediated signaling events—PIK3CA—uterine cancer	0.000382	0.00974	CbGpPWpGaD
Octreotide—MPO—Selenium Micronutrient Network—CCL2—uterine cancer	0.000381	0.00971	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000375	0.00958	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.000347	0.00887	CbGpPWpGaD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000347	0.00884	CbGpPWpGaD
Octreotide—SSTR4—G alpha (i) signalling events—CXCL8—uterine cancer	0.000345	0.00879	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000344	0.00879	CbGpPWpGaD
Octreotide—SSTR5—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000333	0.00849	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—AKR1B10—uterine cancer	0.000332	0.00848	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.000321	0.00818	CbGpPWpGaD
Octreotide—SSTR3—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.00031	0.0079	CbGpPWpGaD
Octreotide—SSTR2—Peptide ligand-binding receptors—CCL2—uterine cancer	0.000307	0.00784	CbGpPWpGaD
Octreotide—MPO—C-MYB transcription factor network—CDKN1B—uterine cancer	0.000305	0.00778	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—EP300—uterine cancer	0.000298	0.0076	CbGpPWpGaD
Octreotide—SSTR1—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000297	0.00757	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—CXCL8—uterine cancer	0.000284	0.00726	CbGpPWpGaD
Octreotide—SSTR1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.000282	0.0072	CbGpPWpGaD
Octreotide—Dehydration—Epirubicin—uterine cancer	0.00028	0.000568	CcSEcCtD
Octreotide—Hypertension—Etoposide—uterine cancer	0.000279	0.000566	CcSEcCtD
Octreotide—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000278	0.000565	CcSEcCtD
Octreotide—Pain in extremity—Doxorubicin—uterine cancer	0.000278	0.000565	CcSEcCtD
Octreotide—Osteoarthritis—Doxorubicin—uterine cancer	0.000278	0.000565	CcSEcCtD
Octreotide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000278	0.000563	CcSEcCtD
Octreotide—Dry skin—Epirubicin—uterine cancer	0.000276	0.000559	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—RNF43—uterine cancer	0.000275	0.00703	CbGpPWpGaD
Octreotide—Chest pain—Etoposide—uterine cancer	0.000275	0.000558	CcSEcCtD
Octreotide—Abdominal pain upper—Epirubicin—uterine cancer	0.000275	0.000557	CcSEcCtD
Octreotide—SSTR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000274	0.00699	CbGpPWpGaD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000273	0.000554	CcSEcCtD
Octreotide—Discomfort—Etoposide—uterine cancer	0.000272	0.000552	CcSEcCtD
Octreotide—Nasopharyngitis—Epirubicin—uterine cancer	0.000269	0.000546	CcSEcCtD
Octreotide—Hypersensitivity—Dactinomycin—uterine cancer	0.000269	0.000545	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—EP300—uterine cancer	0.000268	0.00684	CbGpPWpGaD
Octreotide—Gastritis—Epirubicin—uterine cancer	0.000266	0.00054	CcSEcCtD
Octreotide—Muscular weakness—Epirubicin—uterine cancer	0.000265	0.000538	CcSEcCtD
Octreotide—SSTR4—GPCR ligand binding—CCL2—uterine cancer	0.000264	0.00673	CbGpPWpGaD
Octreotide—Anaphylactic shock—Etoposide—uterine cancer	0.000264	0.000535	CcSEcCtD
Octreotide—SSTR5—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000263	0.00672	CbGpPWpGaD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000263	0.0067	CbGpPWpGaD
Octreotide—SSTR2—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	0.000262	0.00669	CbGpPWpGaD
Octreotide—Infection—Etoposide—uterine cancer	0.000262	0.000532	CcSEcCtD
Octreotide—Abdominal distension—Epirubicin—uterine cancer	0.000262	0.000531	CcSEcCtD
Octreotide—Asthenia—Dactinomycin—uterine cancer	0.000262	0.00053	CcSEcCtD
Octreotide—SSTR3—G alpha (i) signalling events—CXCL8—uterine cancer	0.000261	0.00666	CbGpPWpGaD
Octreotide—Influenza—Epirubicin—uterine cancer	0.00026	0.000527	CcSEcCtD
Octreotide—Asthma—Epirubicin—uterine cancer	0.00026	0.000527	CcSEcCtD
Octreotide—Dehydration—Doxorubicin—uterine cancer	0.000259	0.000525	CcSEcCtD
Octreotide—Thrombocytopenia—Etoposide—uterine cancer	0.000258	0.000524	CcSEcCtD
Octreotide—Tachycardia—Etoposide—uterine cancer	0.000258	0.000522	CcSEcCtD
Octreotide—Skin disorder—Etoposide—uterine cancer	0.000256	0.00052	CcSEcCtD
Octreotide—Dry skin—Doxorubicin—uterine cancer	0.000255	0.000518	CcSEcCtD
Octreotide—Hyperhidrosis—Etoposide—uterine cancer	0.000255	0.000517	CcSEcCtD
Octreotide—Pancreatitis—Epirubicin—uterine cancer	0.000255	0.000517	CcSEcCtD
Octreotide—Abdominal pain upper—Doxorubicin—uterine cancer	0.000254	0.000516	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—AKR1B10—uterine cancer	0.000252	0.00643	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—INHBA—uterine cancer	0.000252	0.00643	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000252	0.00642	CbGpPWpGaD
Octreotide—Anorexia—Etoposide—uterine cancer	0.000251	0.00051	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—NRAS—uterine cancer	0.000251	0.00639	CbGpPWpGaD
Octreotide—SSTR1—G alpha (i) signalling events—CXCL8—uterine cancer	0.00025	0.00639	CbGpPWpGaD
Octreotide—Bronchitis—Epirubicin—uterine cancer	0.00025	0.000507	CcSEcCtD
Octreotide—Diarrhoea—Dactinomycin—uterine cancer	0.000249	0.000506	CcSEcCtD
Octreotide—Nasopharyngitis—Doxorubicin—uterine cancer	0.000249	0.000505	CcSEcCtD
Octreotide—Gastritis—Doxorubicin—uterine cancer	0.000246	0.0005	CcSEcCtD
Octreotide—Muscular weakness—Doxorubicin—uterine cancer	0.000246	0.000498	CcSEcCtD
Octreotide—SSTR2—SIDS Susceptibility Pathways—EP300—uterine cancer	0.000244	0.00622	CbGpPWpGaD
Octreotide—Dysuria—Epirubicin—uterine cancer	0.000243	0.000493	CcSEcCtD
Octreotide—SSTR2—Peptide ligand-binding receptors—CXCL8—uterine cancer	0.000243	0.0062	CbGpPWpGaD
Octreotide—Abdominal distension—Doxorubicin—uterine cancer	0.000242	0.000491	CcSEcCtD
Octreotide—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000242	0.00049	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—AKR1B10—uterine cancer	0.000242	0.00616	CbGpPWpGaD
Octreotide—Asthma—Doxorubicin—uterine cancer	0.000241	0.000488	CcSEcCtD
Octreotide—Influenza—Doxorubicin—uterine cancer	0.000241	0.000488	CcSEcCtD
Octreotide—Pollakiuria—Epirubicin—uterine cancer	0.00024	0.000487	CcSEcCtD
Octreotide—Paraesthesia—Etoposide—uterine cancer	0.000237	0.000481	CcSEcCtD
Octreotide—Weight increased—Epirubicin—uterine cancer	0.000237	0.00048	CcSEcCtD
Octreotide—Pancreatitis—Doxorubicin—uterine cancer	0.000236	0.000479	CcSEcCtD
Octreotide—Weight decreased—Epirubicin—uterine cancer	0.000235	0.000477	CcSEcCtD
Octreotide—Dyspnoea—Etoposide—uterine cancer	0.000235	0.000477	CcSEcCtD
Octreotide—Hyperglycaemia—Epirubicin—uterine cancer	0.000235	0.000476	CcSEcCtD
Octreotide—Somnolence—Etoposide—uterine cancer	0.000235	0.000476	CcSEcCtD
Octreotide—Pneumonia—Epirubicin—uterine cancer	0.000233	0.000473	CcSEcCtD
Octreotide—MPO—Folate Metabolism—TP53—uterine cancer	0.000233	0.00593	CbGpPWpGaD
Octreotide—Drowsiness—Epirubicin—uterine cancer	0.000232	0.00047	CcSEcCtD
Octreotide—Vomiting—Dactinomycin—uterine cancer	0.000232	0.00047	CcSEcCtD
Octreotide—Bronchitis—Doxorubicin—uterine cancer	0.000231	0.000469	CcSEcCtD
Octreotide—SSTR2—SIDS Susceptibility Pathways—VEGFA—uterine cancer	0.000231	0.00589	CbGpPWpGaD
Octreotide—Rash—Dactinomycin—uterine cancer	0.00023	0.000466	CcSEcCtD
Octreotide—Decreased appetite—Etoposide—uterine cancer	0.000229	0.000465	CcSEcCtD
Octreotide—Gastrointestinal disorder—Etoposide—uterine cancer	0.000228	0.000462	CcSEcCtD
Octreotide—Fatigue—Etoposide—uterine cancer	0.000227	0.000461	CcSEcCtD
Octreotide—Neuropathy peripheral—Epirubicin—uterine cancer	0.000227	0.000461	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—AKR1C1—uterine cancer	0.000227	0.00579	CbGpPWpGaD
Octreotide—Jaundice—Epirubicin—uterine cancer	0.000226	0.000458	CcSEcCtD
Octreotide—Constipation—Etoposide—uterine cancer	0.000226	0.000458	CcSEcCtD
Octreotide—Pain—Etoposide—uterine cancer	0.000226	0.000458	CcSEcCtD
Octreotide—Conjunctivitis—Epirubicin—uterine cancer	0.000225	0.000457	CcSEcCtD
Octreotide—Urinary tract infection—Epirubicin—uterine cancer	0.000225	0.000457	CcSEcCtD
Octreotide—Dysuria—Doxorubicin—uterine cancer	0.000225	0.000456	CcSEcCtD
Octreotide—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000224	0.000454	CcSEcCtD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000223	0.0057	CbGpPWpGaD
Octreotide—Pollakiuria—Doxorubicin—uterine cancer	0.000222	0.000451	CcSEcCtD
Octreotide—SSTR5—G alpha (i) signalling events—CXCL8—uterine cancer	0.000222	0.00567	CbGpPWpGaD
Octreotide—Haematuria—Epirubicin—uterine cancer	0.000221	0.000448	CcSEcCtD
Octreotide—Hepatobiliary disease—Epirubicin—uterine cancer	0.000219	0.000445	CcSEcCtD
Octreotide—Weight increased—Doxorubicin—uterine cancer	0.000219	0.000444	CcSEcCtD
Octreotide—Epistaxis—Epirubicin—uterine cancer	0.000219	0.000444	CcSEcCtD
Octreotide—Weight decreased—Doxorubicin—uterine cancer	0.000218	0.000442	CcSEcCtD
Octreotide—Sinusitis—Epirubicin—uterine cancer	0.000218	0.000441	CcSEcCtD
Octreotide—Feeling abnormal—Etoposide—uterine cancer	0.000217	0.000441	CcSEcCtD
Octreotide—Hyperglycaemia—Doxorubicin—uterine cancer	0.000217	0.00044	CcSEcCtD
Octreotide—Nausea—Dactinomycin—uterine cancer	0.000217	0.000439	CcSEcCtD
Octreotide—Pneumonia—Doxorubicin—uterine cancer	0.000216	0.000438	CcSEcCtD
Octreotide—Gastrointestinal pain—Etoposide—uterine cancer	0.000216	0.000438	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—KRAS—uterine cancer	0.000216	0.0055	CbGpPWpGaD
Octreotide—Drowsiness—Doxorubicin—uterine cancer	0.000215	0.000435	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—AKR1B10—uterine cancer	0.000214	0.00547	CbGpPWpGaD
Octreotide—Bradycardia—Epirubicin—uterine cancer	0.000212	0.00043	CcSEcCtD
Octreotide—Neuropathy peripheral—Doxorubicin—uterine cancer	0.00021	0.000427	CcSEcCtD
Octreotide—Urticaria—Etoposide—uterine cancer	0.00021	0.000425	CcSEcCtD
Octreotide—Jaundice—Doxorubicin—uterine cancer	0.000209	0.000424	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—RNF43—uterine cancer	0.000209	0.00533	CbGpPWpGaD
Octreotide—Rhinitis—Epirubicin—uterine cancer	0.000209	0.000423	CcSEcCtD
Octreotide—SSTR4—GPCR ligand binding—CXCL8—uterine cancer	0.000209	0.00532	CbGpPWpGaD
Octreotide—Body temperature increased—Etoposide—uterine cancer	0.000209	0.000423	CcSEcCtD
Octreotide—Abdominal pain—Etoposide—uterine cancer	0.000209	0.000423	CcSEcCtD
Octreotide—Conjunctivitis—Doxorubicin—uterine cancer	0.000209	0.000423	CcSEcCtD
Octreotide—Urinary tract infection—Doxorubicin—uterine cancer	0.000209	0.000423	CcSEcCtD
Octreotide—Hepatitis—Epirubicin—uterine cancer	0.000208	0.000422	CcSEcCtD
Octreotide—SSTR3—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000208	0.0053	CbGpPWpGaD
Octreotide—Hypoaesthesia—Epirubicin—uterine cancer	0.000207	0.00042	CcSEcCtD
Octreotide—Pharyngitis—Epirubicin—uterine cancer	0.000207	0.000419	CcSEcCtD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000206	0.00526	CbGpPWpGaD
Octreotide—Oedema peripheral—Epirubicin—uterine cancer	0.000205	0.000416	CcSEcCtD
Octreotide—SSTR2—G alpha (i) signalling events—CXCL8—uterine cancer	0.000205	0.00523	CbGpPWpGaD
Octreotide—Haematuria—Doxorubicin—uterine cancer	0.000205	0.000415	CcSEcCtD
Octreotide—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000203	0.000412	CcSEcCtD
Octreotide—Epistaxis—Doxorubicin—uterine cancer	0.000202	0.00041	CcSEcCtD
Octreotide—Sinusitis—Doxorubicin—uterine cancer	0.000201	0.000408	CcSEcCtD
Octreotide—Visual impairment—Epirubicin—uterine cancer	0.000201	0.000407	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—RNF43—uterine cancer	0.0002	0.00511	CbGpPWpGaD
Octreotide—SSTR3—GPCR ligand binding—CCL2—uterine cancer	0.0002	0.0051	CbGpPWpGaD
Octreotide—SSTR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000199	0.00508	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKR1B10—uterine cancer	0.000198	0.00504	CbGpPWpGaD
Octreotide—Bradycardia—Doxorubicin—uterine cancer	0.000196	0.000398	CcSEcCtD
Octreotide—Hypersensitivity—Etoposide—uterine cancer	0.000194	0.000394	CcSEcCtD
Octreotide—Tinnitus—Epirubicin—uterine cancer	0.000194	0.000394	CcSEcCtD
Octreotide—Flushing—Epirubicin—uterine cancer	0.000193	0.000392	CcSEcCtD
Octreotide—Cardiac disorder—Epirubicin—uterine cancer	0.000193	0.000392	CcSEcCtD
Octreotide—Rhinitis—Doxorubicin—uterine cancer	0.000193	0.000392	CcSEcCtD
Octreotide—Hepatitis—Doxorubicin—uterine cancer	0.000193	0.000391	CcSEcCtD
Octreotide—SSTR1—GPCR ligand binding—CCL2—uterine cancer	0.000192	0.00489	CbGpPWpGaD
Octreotide—Hypoaesthesia—Doxorubicin—uterine cancer	0.000192	0.000389	CcSEcCtD
Octreotide—Pharyngitis—Doxorubicin—uterine cancer	0.000191	0.000388	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—INHBA—uterine cancer	0.000191	0.00487	CbGpPWpGaD
Octreotide—Oedema peripheral—Doxorubicin—uterine cancer	0.00019	0.000385	CcSEcCtD
Octreotide—Asthenia—Etoposide—uterine cancer	0.000189	0.000384	CcSEcCtD
Octreotide—Immune system disorder—Epirubicin—uterine cancer	0.000188	0.000381	CcSEcCtD
Octreotide—Pruritus—Etoposide—uterine cancer	0.000187	0.000379	CcSEcCtD
Octreotide—Arrhythmia—Epirubicin—uterine cancer	0.000186	0.000377	CcSEcCtD
Octreotide—Visual impairment—Doxorubicin—uterine cancer	0.000186	0.000376	CcSEcCtD
Octreotide—Alopecia—Epirubicin—uterine cancer	0.000184	0.000373	CcSEcCtD
Octreotide—MPO—C-MYB transcription factor network—HRAS—uterine cancer	0.000183	0.00468	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—INHBA—uterine cancer	0.000183	0.00467	CbGpPWpGaD
Octreotide—Mental disorder—Epirubicin—uterine cancer	0.000182	0.00037	CcSEcCtD
Octreotide—Malnutrition—Epirubicin—uterine cancer	0.000181	0.000368	CcSEcCtD
Octreotide—Erythema—Epirubicin—uterine cancer	0.000181	0.000368	CcSEcCtD
Octreotide—Diarrhoea—Etoposide—uterine cancer	0.000181	0.000366	CcSEcCtD
Octreotide—Tinnitus—Doxorubicin—uterine cancer	0.00018	0.000364	CcSEcCtD
Octreotide—Flushing—Doxorubicin—uterine cancer	0.000179	0.000363	CcSEcCtD
Octreotide—Cardiac disorder—Doxorubicin—uterine cancer	0.000179	0.000363	CcSEcCtD
Octreotide—Flatulence—Epirubicin—uterine cancer	0.000179	0.000362	CcSEcCtD
Octreotide—Tension—Epirubicin—uterine cancer	0.000178	0.000361	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—RNF43—uterine cancer	0.000177	0.00453	CbGpPWpGaD
Octreotide—SSTR5—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000177	0.0045	CbGpPWpGaD
Octreotide—Nervousness—Epirubicin—uterine cancer	0.000176	0.000357	CcSEcCtD
Octreotide—Back pain—Epirubicin—uterine cancer	0.000175	0.000356	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—AKR1C3—uterine cancer	0.000175	0.00446	CbGpPWpGaD
Octreotide—Dizziness—Etoposide—uterine cancer	0.000174	0.000354	CcSEcCtD
Octreotide—Muscle spasms—Epirubicin—uterine cancer	0.000174	0.000353	CcSEcCtD
Octreotide—Immune system disorder—Doxorubicin—uterine cancer	0.000174	0.000353	CcSEcCtD
Octreotide—Arrhythmia—Doxorubicin—uterine cancer	0.000172	0.000349	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—AKR1C1—uterine cancer	0.000172	0.00439	CbGpPWpGaD
Octreotide—Vision blurred—Epirubicin—uterine cancer	0.000171	0.000346	CcSEcCtD
Octreotide—Alopecia—Doxorubicin—uterine cancer	0.00017	0.000345	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—PGR—uterine cancer	0.00017	0.00434	CbGpPWpGaD
Octreotide—SSTR5—GPCR ligand binding—CCL2—uterine cancer	0.00017	0.00434	CbGpPWpGaD
Octreotide—Mental disorder—Doxorubicin—uterine cancer	0.000169	0.000342	CcSEcCtD
Octreotide—Ill-defined disorder—Epirubicin—uterine cancer	0.000168	0.000341	CcSEcCtD
Octreotide—Vomiting—Etoposide—uterine cancer	0.000168	0.00034	CcSEcCtD
Octreotide—Erythema—Doxorubicin—uterine cancer	0.000168	0.00034	CcSEcCtD
Octreotide—Malnutrition—Doxorubicin—uterine cancer	0.000168	0.00034	CcSEcCtD
Octreotide—Anaemia—Epirubicin—uterine cancer	0.000167	0.00034	CcSEcCtD
Octreotide—Agitation—Epirubicin—uterine cancer	0.000167	0.000338	CcSEcCtD
Octreotide—Rash—Etoposide—uterine cancer	0.000166	0.000337	CcSEcCtD
Octreotide—Dermatitis—Etoposide—uterine cancer	0.000166	0.000337	CcSEcCtD
Octreotide—Headache—Etoposide—uterine cancer	0.000165	0.000335	CcSEcCtD
Octreotide—Flatulence—Doxorubicin—uterine cancer	0.000165	0.000335	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—AKR1C1—uterine cancer	0.000165	0.00421	CbGpPWpGaD
Octreotide—Tension—Doxorubicin—uterine cancer	0.000165	0.000334	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—RNF43—uterine cancer	0.000164	0.00418	CbGpPWpGaD
Octreotide—Malaise—Epirubicin—uterine cancer	0.000163	0.000331	CcSEcCtD
Octreotide—SSTR2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000163	0.00416	CbGpPWpGaD
Octreotide—Nervousness—Doxorubicin—uterine cancer	0.000163	0.00033	CcSEcCtD
Octreotide—Vertigo—Epirubicin—uterine cancer	0.000163	0.00033	CcSEcCtD
Octreotide—Syncope—Epirubicin—uterine cancer	0.000163	0.00033	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—INHBA—uterine cancer	0.000162	0.00414	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—YWHAE—uterine cancer	0.000162	0.00414	CbGpPWpGaD
Octreotide—Back pain—Doxorubicin—uterine cancer	0.000162	0.000329	CcSEcCtD
Octreotide—Muscle spasms—Doxorubicin—uterine cancer	0.000161	0.000327	CcSEcCtD
Octreotide—Palpitations—Epirubicin—uterine cancer	0.00016	0.000325	CcSEcCtD
Octreotide—Loss of consciousness—Epirubicin—uterine cancer	0.000159	0.000323	CcSEcCtD
Octreotide—Cough—Epirubicin—uterine cancer	0.000158	0.000321	CcSEcCtD
Octreotide—SSTR3—GPCR ligand binding—CXCL8—uterine cancer	0.000158	0.00403	CbGpPWpGaD
Octreotide—Vision blurred—Doxorubicin—uterine cancer	0.000158	0.000321	CcSEcCtD
Octreotide—Convulsion—Epirubicin—uterine cancer	0.000157	0.000318	CcSEcCtD
Octreotide—SSTR2—GPCR ligand binding—CCL2—uterine cancer	0.000157	0.004	CbGpPWpGaD
Octreotide—Nausea—Etoposide—uterine cancer	0.000157	0.000318	CcSEcCtD
Octreotide—Hypertension—Epirubicin—uterine cancer	0.000156	0.000317	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—FBXW7—uterine cancer	0.000156	0.00397	CbGpPWpGaD
Octreotide—Ill-defined disorder—Doxorubicin—uterine cancer	0.000156	0.000316	CcSEcCtD
Octreotide—Anaemia—Doxorubicin—uterine cancer	0.000155	0.000314	CcSEcCtD
Octreotide—Chest pain—Epirubicin—uterine cancer	0.000154	0.000313	CcSEcCtD
Octreotide—Arthralgia—Epirubicin—uterine cancer	0.000154	0.000313	CcSEcCtD
Octreotide—Myalgia—Epirubicin—uterine cancer	0.000154	0.000313	CcSEcCtD
Octreotide—Agitation—Doxorubicin—uterine cancer	0.000154	0.000313	CcSEcCtD
Octreotide—Anxiety—Epirubicin—uterine cancer	0.000154	0.000312	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000153	0.000311	CcSEcCtD
Octreotide—Discomfort—Epirubicin—uterine cancer	0.000152	0.000309	CcSEcCtD
Octreotide—SSTR1—GPCR ligand binding—CXCL8—uterine cancer	0.000152	0.00387	CbGpPWpGaD
Octreotide—Malaise—Doxorubicin—uterine cancer	0.000151	0.000307	CcSEcCtD
Octreotide—Dry mouth—Epirubicin—uterine cancer	0.000151	0.000306	CcSEcCtD
Octreotide—Vertigo—Doxorubicin—uterine cancer	0.000151	0.000306	CcSEcCtD
Octreotide—Syncope—Doxorubicin—uterine cancer	0.00015	0.000305	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—INHBA—uterine cancer	0.00015	0.00382	CbGpPWpGaD
Octreotide—Palpitations—Doxorubicin—uterine cancer	0.000148	0.000301	CcSEcCtD
Octreotide—Anaphylactic shock—Epirubicin—uterine cancer	0.000148	0.0003	CcSEcCtD
Octreotide—Oedema—Epirubicin—uterine cancer	0.000148	0.0003	CcSEcCtD
Octreotide—Loss of consciousness—Doxorubicin—uterine cancer	0.000147	0.000299	CcSEcCtD
Octreotide—Infection—Epirubicin—uterine cancer	0.000147	0.000298	CcSEcCtD
Octreotide—Cough—Doxorubicin—uterine cancer	0.000146	0.000297	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—AKR1C1—uterine cancer	0.000146	0.00373	CbGpPWpGaD
Octreotide—Shock—Epirubicin—uterine cancer	0.000146	0.000295	CcSEcCtD
Octreotide—Convulsion—Doxorubicin—uterine cancer	0.000145	0.000295	CcSEcCtD
Octreotide—Nervous system disorder—Epirubicin—uterine cancer	0.000145	0.000294	CcSEcCtD
Octreotide—Thrombocytopenia—Epirubicin—uterine cancer	0.000145	0.000294	CcSEcCtD
Octreotide—Hypertension—Doxorubicin—uterine cancer	0.000145	0.000294	CcSEcCtD
Octreotide—Tachycardia—Epirubicin—uterine cancer	0.000144	0.000293	CcSEcCtD
Octreotide—Skin disorder—Epirubicin—uterine cancer	0.000144	0.000291	CcSEcCtD
Octreotide—Hyperhidrosis—Epirubicin—uterine cancer	0.000143	0.00029	CcSEcCtD
Octreotide—Chest pain—Doxorubicin—uterine cancer	0.000143	0.00029	CcSEcCtD
Octreotide—Arthralgia—Doxorubicin—uterine cancer	0.000143	0.00029	CcSEcCtD
Octreotide—Myalgia—Doxorubicin—uterine cancer	0.000143	0.00029	CcSEcCtD
Octreotide—Anxiety—Doxorubicin—uterine cancer	0.000142	0.000289	CcSEcCtD
Octreotide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000142	0.000288	CcSEcCtD
Octreotide—Discomfort—Doxorubicin—uterine cancer	0.000141	0.000286	CcSEcCtD
Octreotide—Anorexia—Epirubicin—uterine cancer	0.000141	0.000286	CcSEcCtD
Octreotide—Dry mouth—Doxorubicin—uterine cancer	0.00014	0.000283	CcSEcCtD
Octreotide—Anaphylactic shock—Doxorubicin—uterine cancer	0.000137	0.000278	CcSEcCtD
Octreotide—Oedema—Doxorubicin—uterine cancer	0.000137	0.000278	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—STK11—uterine cancer	0.000136	0.00347	CbGpPWpGaD
Octreotide—Infection—Doxorubicin—uterine cancer	0.000136	0.000276	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—CCL2—uterine cancer	0.000135	0.00346	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKR1C1—uterine cancer	0.000135	0.00344	CbGpPWpGaD
Octreotide—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.000135	0.000273	CcSEcCtD
Octreotide—Shock—Doxorubicin—uterine cancer	0.000135	0.000273	CcSEcCtD
Octreotide—SSTR5—GPCR ligand binding—CXCL8—uterine cancer	0.000134	0.00343	CbGpPWpGaD
Octreotide—Nervous system disorder—Doxorubicin—uterine cancer	0.000134	0.000272	CcSEcCtD
Octreotide—Thrombocytopenia—Doxorubicin—uterine cancer	0.000134	0.000272	CcSEcCtD
Octreotide—Insomnia—Epirubicin—uterine cancer	0.000134	0.000271	CcSEcCtD
Octreotide—Tachycardia—Doxorubicin—uterine cancer	0.000134	0.000271	CcSEcCtD
Octreotide—Skin disorder—Doxorubicin—uterine cancer	0.000133	0.00027	CcSEcCtD
Octreotide—Paraesthesia—Epirubicin—uterine cancer	0.000133	0.000269	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—AKR1C3—uterine cancer	0.000132	0.00338	CbGpPWpGaD
Octreotide—Hyperhidrosis—Doxorubicin—uterine cancer	0.000132	0.000268	CcSEcCtD
Octreotide—Dyspnoea—Epirubicin—uterine cancer	0.000132	0.000267	CcSEcCtD
Octreotide—Somnolence—Epirubicin—uterine cancer	0.000131	0.000267	CcSEcCtD
Octreotide—Anorexia—Doxorubicin—uterine cancer	0.00013	0.000265	CcSEcCtD
Octreotide—Dyspepsia—Epirubicin—uterine cancer	0.00013	0.000264	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—PGR—uterine cancer	0.000129	0.00329	CbGpPWpGaD
Octreotide—Decreased appetite—Epirubicin—uterine cancer	0.000129	0.000261	CcSEcCtD
Octreotide—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000128	0.000259	CcSEcCtD
Octreotide—Fatigue—Epirubicin—uterine cancer	0.000128	0.000259	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—SOCS3—uterine cancer	0.000127	0.00325	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—AKR1C3—uterine cancer	0.000127	0.00324	CbGpPWpGaD
Octreotide—Constipation—Epirubicin—uterine cancer	0.000126	0.000257	CcSEcCtD
Octreotide—Pain—Epirubicin—uterine cancer	0.000126	0.000257	CcSEcCtD
Octreotide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000125	0.000253	CcSEcCtD
Octreotide—SSTR2—GPCR ligand binding—CXCL8—uterine cancer	0.000124	0.00317	CbGpPWpGaD
Octreotide—Insomnia—Doxorubicin—uterine cancer	0.000124	0.000251	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—PGR—uterine cancer	0.000124	0.00315	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—YWHAE—uterine cancer	0.000123	0.00314	CbGpPWpGaD
Octreotide—Paraesthesia—Doxorubicin—uterine cancer	0.000123	0.000249	CcSEcCtD
Octreotide—Dyspnoea—Doxorubicin—uterine cancer	0.000122	0.000247	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—CDKN2B—uterine cancer	0.000122	0.00311	CbGpPWpGaD
Octreotide—Feeling abnormal—Epirubicin—uterine cancer	0.000122	0.000247	CcSEcCtD
Octreotide—Somnolence—Doxorubicin—uterine cancer	0.000122	0.000247	CcSEcCtD
Octreotide—Gastrointestinal pain—Epirubicin—uterine cancer	0.000121	0.000245	CcSEcCtD
Octreotide—Dyspepsia—Doxorubicin—uterine cancer	0.00012	0.000244	CcSEcCtD
Octreotide—Decreased appetite—Doxorubicin—uterine cancer	0.000119	0.000241	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—IGF1R—uterine cancer	0.000118	0.00302	CbGpPWpGaD
Octreotide—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000118	0.00024	CcSEcCtD
Octreotide—Fatigue—Doxorubicin—uterine cancer	0.000118	0.000239	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—FBXW7—uterine cancer	0.000118	0.00301	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—YWHAE—uterine cancer	0.000118	0.00301	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—CXCL8—uterine cancer	0.000118	0.00301	CbGpPWpGaD
Octreotide—Urticaria—Epirubicin—uterine cancer	0.000117	0.000238	CcSEcCtD
Octreotide—Constipation—Doxorubicin—uterine cancer	0.000117	0.000237	CcSEcCtD
Octreotide—Pain—Doxorubicin—uterine cancer	0.000117	0.000237	CcSEcCtD
Octreotide—Body temperature increased—Epirubicin—uterine cancer	0.000117	0.000237	CcSEcCtD
Octreotide—Abdominal pain—Epirubicin—uterine cancer	0.000117	0.000237	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—FBXW7—uterine cancer	0.000113	0.00289	CbGpPWpGaD
Octreotide—Feeling abnormal—Doxorubicin—uterine cancer	0.000113	0.000229	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—AKR1C3—uterine cancer	0.000113	0.00287	CbGpPWpGaD
Octreotide—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000112	0.000227	CcSEcCtD
Octreotide—SSTR4—Signaling Pathways—SMAD3—uterine cancer	0.000111	0.00284	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PGR—uterine cancer	0.00011	0.0028	CbGpPWpGaD
Octreotide—Hypersensitivity—Epirubicin—uterine cancer	0.000109	0.000221	CcSEcCtD
Octreotide—Urticaria—Doxorubicin—uterine cancer	0.000109	0.00022	CcSEcCtD
Octreotide—Abdominal pain—Doxorubicin—uterine cancer	0.000108	0.000219	CcSEcCtD
Octreotide—Body temperature increased—Doxorubicin—uterine cancer	0.000108	0.000219	CcSEcCtD
Octreotide—SSTR4—Signaling by GPCR—CXCL8—uterine cancer	0.000107	0.00273	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—FGFR2—uterine cancer	0.000106	0.00271	CbGpPWpGaD
Octreotide—Asthenia—Epirubicin—uterine cancer	0.000106	0.000215	CcSEcCtD
Octreotide—Pruritus—Epirubicin—uterine cancer	0.000105	0.000212	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—YWHAE—uterine cancer	0.000105	0.00267	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKR1C3—uterine cancer	0.000104	0.00265	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—STK11—uterine cancer	0.000103	0.00263	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—CCL2—uterine cancer	0.000103	0.00262	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PGR—uterine cancer	0.000101	0.00258	CbGpPWpGaD
Octreotide—Diarrhoea—Epirubicin—uterine cancer	0.000101	0.000205	CcSEcCtD
Octreotide—Hypersensitivity—Doxorubicin—uterine cancer	0.000101	0.000204	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—FBXW7—uterine cancer	0.0001	0.00256	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—STK11—uterine cancer	9.88e-05	0.00252	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—CCL2—uterine cancer	9.84e-05	0.00251	CbGpPWpGaD
Octreotide—Asthenia—Doxorubicin—uterine cancer	9.82e-05	0.000199	CcSEcCtD
Octreotide—Dizziness—Epirubicin—uterine cancer	9.78e-05	0.000198	CcSEcCtD
Octreotide—Pruritus—Doxorubicin—uterine cancer	9.68e-05	0.000196	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—SOCS3—uterine cancer	9.65e-05	0.00246	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—YWHAE—uterine cancer	9.65e-05	0.00246	CbGpPWpGaD
Octreotide—Vomiting—Epirubicin—uterine cancer	9.4e-05	0.000191	CcSEcCtD
Octreotide—Diarrhoea—Doxorubicin—uterine cancer	9.36e-05	0.00019	CcSEcCtD
Octreotide—Rash—Epirubicin—uterine cancer	9.33e-05	0.000189	CcSEcCtD
Octreotide—Dermatitis—Epirubicin—uterine cancer	9.32e-05	0.000189	CcSEcCtD
Octreotide—Headache—Epirubicin—uterine cancer	9.27e-05	0.000188	CcSEcCtD
Octreotide—SSTR2—Signaling Pathways—FBXW7—uterine cancer	9.26e-05	0.00236	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SOCS3—uterine cancer	9.26e-05	0.00236	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CDKN2B—uterine cancer	9.24e-05	0.00236	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—ESR1—uterine cancer	9.09e-05	0.00232	CbGpPWpGaD
Octreotide—Dizziness—Doxorubicin—uterine cancer	9.05e-05	0.000184	CcSEcCtD
Octreotide—SSTR3—Signaling Pathways—IGF1R—uterine cancer	8.98e-05	0.00229	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—CXCL8—uterine cancer	8.94e-05	0.00228	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CDKN2B—uterine cancer	8.86e-05	0.00226	CbGpPWpGaD
Octreotide—Nausea—Epirubicin—uterine cancer	8.78e-05	0.000178	CcSEcCtD
Octreotide—SSTR5—Signaling Pathways—STK11—uterine cancer	8.77e-05	0.00224	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—CCL2—uterine cancer	8.73e-05	0.00223	CbGpPWpGaD
Octreotide—Vomiting—Doxorubicin—uterine cancer	8.7e-05	0.000176	CcSEcCtD
Octreotide—Rash—Doxorubicin—uterine cancer	8.63e-05	0.000175	CcSEcCtD
Octreotide—Dermatitis—Doxorubicin—uterine cancer	8.62e-05	0.000175	CcSEcCtD
Octreotide—SSTR1—Signaling Pathways—IGF1R—uterine cancer	8.6e-05	0.0022	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—NRAS—uterine cancer	8.59e-05	0.00219	CbGpPWpGaD
Octreotide—Headache—Doxorubicin—uterine cancer	8.57e-05	0.000174	CcSEcCtD
Octreotide—SSTR1—GPCR downstream signaling—CXCL8—uterine cancer	8.57e-05	0.00219	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—SMAD3—uterine cancer	8.44e-05	0.00215	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SOCS3—uterine cancer	8.21e-05	0.00209	CbGpPWpGaD
Octreotide—Nausea—Doxorubicin—uterine cancer	8.13e-05	0.000165	CcSEcCtD
Octreotide—SSTR3—Signaling by GPCR—CXCL8—uterine cancer	8.11e-05	0.00207	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—STK11—uterine cancer	8.09e-05	0.00206	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—SMAD3—uterine cancer	8.09e-05	0.00206	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—CCL2—uterine cancer	8.05e-05	0.00205	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—FGFR2—uterine cancer	8.05e-05	0.00205	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CCL2—uterine cancer	8e-05	0.00204	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN2B—uterine cancer	7.86e-05	0.00201	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—CXCL8—uterine cancer	7.78e-05	0.00198	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—FGFR2—uterine cancer	7.72e-05	0.00197	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—IGF1R—uterine cancer	7.63e-05	0.00195	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—CXCL8—uterine cancer	7.6e-05	0.00194	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SOCS3—uterine cancer	7.58e-05	0.00193	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—PIK3CA—uterine cancer	7.48e-05	0.00191	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—KRAS—uterine cancer	7.39e-05	0.00189	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN2B—uterine cancer	7.25e-05	0.00185	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—SMAD3—uterine cancer	7.18e-05	0.00183	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—IGF1R—uterine cancer	7.04e-05	0.0018	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—CXCL8—uterine cancer	7.01e-05	0.00179	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—CXCL8—uterine cancer	6.9e-05	0.00176	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ESR1—uterine cancer	6.89e-05	0.00176	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—FGFR2—uterine cancer	6.84e-05	0.00175	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—PIK3CA—uterine cancer	6.79e-05	0.00173	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—ERBB2—uterine cancer	6.67e-05	0.0017	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—SMAD3—uterine cancer	6.62e-05	0.00169	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ESR1—uterine cancer	6.6e-05	0.00168	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—NRAS—uterine cancer	6.51e-05	0.00166	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—CXCL8—uterine cancer	6.37e-05	0.00162	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CXCL8—uterine cancer	6.32e-05	0.00161	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—FGFR2—uterine cancer	6.32e-05	0.00161	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—HRAS—uterine cancer	6.28e-05	0.0016	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—NRAS—uterine cancer	6.24e-05	0.00159	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CDKN1B—uterine cancer	6.18e-05	0.00158	CbGpPWpGaD
Octreotide—SSTR4—GPCR downstream signaling—AKT1—uterine cancer	6.11e-05	0.00156	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CCL2—uterine cancer	6.06e-05	0.00155	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ESR1—uterine cancer	5.86e-05	0.00149	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—CTNNB1—uterine cancer	5.84e-05	0.00149	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CCL2—uterine cancer	5.81e-05	0.00148	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PTEN—uterine cancer	5.69e-05	0.00145	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—PIK3CA—uterine cancer	5.67e-05	0.00145	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—KRAS—uterine cancer	5.6e-05	0.00143	CbGpPWpGaD
Octreotide—SSTR4—Signaling by GPCR—AKT1—uterine cancer	5.55e-05	0.00142	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—NRAS—uterine cancer	5.53e-05	0.00141	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—PIK3CA—uterine cancer	5.43e-05	0.00139	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—EP300—uterine cancer	5.42e-05	0.00138	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ESR1—uterine cancer	5.4e-05	0.00138	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—KRAS—uterine cancer	5.37e-05	0.00137	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CCL2—uterine cancer	5.15e-05	0.00132	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—PIK3CA—uterine cancer	5.15e-05	0.00131	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—VEGFA—uterine cancer	5.14e-05	0.00131	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—NRAS—uterine cancer	5.11e-05	0.0013	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—NRAS—uterine cancer	5.07e-05	0.00129	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—ERBB2—uterine cancer	5.05e-05	0.00129	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—PIK3CA—uterine cancer	4.93e-05	0.00126	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—ERBB2—uterine cancer	4.85e-05	0.00124	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—PIK3CA—uterine cancer	4.82e-05	0.00123	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CXCL8—uterine cancer	4.79e-05	0.00122	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—KRAS—uterine cancer	4.76e-05	0.00122	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—HRAS—uterine cancer	4.76e-05	0.00122	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CCL2—uterine cancer	4.76e-05	0.00121	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CDKN1B—uterine cancer	4.68e-05	0.00119	CbGpPWpGaD
Octreotide—SSTR3—GPCR downstream signaling—AKT1—uterine cancer	4.63e-05	0.00118	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CXCL8—uterine cancer	4.6e-05	0.00117	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—HRAS—uterine cancer	4.57e-05	0.00116	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CDKN1B—uterine cancer	4.49e-05	0.00115	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—PIK3CA—uterine cancer	4.45e-05	0.00113	CbGpPWpGaD
Octreotide—SSTR1—GPCR downstream signaling—AKT1—uterine cancer	4.44e-05	0.00113	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—CTNNB1—uterine cancer	4.42e-05	0.00113	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—KRAS—uterine cancer	4.4e-05	0.00112	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—PIK3CA—uterine cancer	4.38e-05	0.00112	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—KRAS—uterine cancer	4.37e-05	0.00111	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PTEN—uterine cancer	4.31e-05	0.0011	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—ERBB2—uterine cancer	4.3e-05	0.0011	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—CTNNB1—uterine cancer	4.24e-05	0.00108	CbGpPWpGaD
Octreotide—SSTR3—Signaling by GPCR—AKT1—uterine cancer	4.2e-05	0.00107	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PTEN—uterine cancer	4.13e-05	0.00105	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—EP300—uterine cancer	4.11e-05	0.00105	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CXCL8—uterine cancer	4.08e-05	0.00104	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—HRAS—uterine cancer	4.05e-05	0.00103	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—PIK3CA—uterine cancer	4.04e-05	0.00103	CbGpPWpGaD
Octreotide—SSTR1—Signaling by GPCR—AKT1—uterine cancer	4.03e-05	0.00103	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—PIK3CA—uterine cancer	4.01e-05	0.00102	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CDKN1B—uterine cancer	3.98e-05	0.00102	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—ERBB2—uterine cancer	3.97e-05	0.00101	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—EP300—uterine cancer	3.94e-05	0.00101	CbGpPWpGaD
Octreotide—SSTR5—GPCR downstream signaling—AKT1—uterine cancer	3.94e-05	0.001	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—VEGFA—uterine cancer	3.89e-05	0.000993	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—TP53—uterine cancer	3.88e-05	0.00099	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—NRAS—uterine cancer	3.85e-05	0.000981	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CXCL8—uterine cancer	3.76e-05	0.00096	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—CTNNB1—uterine cancer	3.76e-05	0.000959	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—HRAS—uterine cancer	3.74e-05	0.000953	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—VEGFA—uterine cancer	3.73e-05	0.000952	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—HRAS—uterine cancer	3.71e-05	0.000947	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—NRAS—uterine cancer	3.69e-05	0.000941	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CDKN1B—uterine cancer	3.67e-05	0.000937	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PTEN—uterine cancer	3.66e-05	0.000935	CbGpPWpGaD
Octreotide—SSTR2—GPCR downstream signaling—AKT1—uterine cancer	3.63e-05	0.000927	CbGpPWpGaD
Octreotide—SSTR5—Signaling by GPCR—AKT1—uterine cancer	3.58e-05	0.000912	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—EP300—uterine cancer	3.49e-05	0.000892	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—CTNNB1—uterine cancer	3.47e-05	0.000885	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PTEN—uterine cancer	3.38e-05	0.000863	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—VEGFA—uterine cancer	3.31e-05	0.000845	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—KRAS—uterine cancer	3.31e-05	0.000844	CbGpPWpGaD
Octreotide—SSTR2—Signaling by GPCR—AKT1—uterine cancer	3.3e-05	0.000842	CbGpPWpGaD
Octreotide—SSTR4—Signaling Pathways—AKT1—uterine cancer	3.28e-05	0.000836	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—NRAS—uterine cancer	3.27e-05	0.000834	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—EP300—uterine cancer	3.23e-05	0.000823	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—KRAS—uterine cancer	3.17e-05	0.00081	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—VEGFA—uterine cancer	3.05e-05	0.000779	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—PIK3CA—uterine cancer	3.04e-05	0.000776	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—NRAS—uterine cancer	3.02e-05	0.00077	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—TP53—uterine cancer	2.94e-05	0.000751	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—PIK3CA—uterine cancer	2.92e-05	0.000744	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—TP53—uterine cancer	2.82e-05	0.00072	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—KRAS—uterine cancer	2.81e-05	0.000718	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—HRAS—uterine cancer	2.81e-05	0.000718	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—HRAS—uterine cancer	2.7e-05	0.000688	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—KRAS—uterine cancer	2.6e-05	0.000663	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—PIK3CA—uterine cancer	2.59e-05	0.00066	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—TP53—uterine cancer	2.5e-05	0.000638	CbGpPWpGaD
Octreotide—SSTR3—Signaling Pathways—AKT1—uterine cancer	2.48e-05	0.000634	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—HRAS—uterine cancer	2.39e-05	0.00061	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—PIK3CA—uterine cancer	2.39e-05	0.000609	CbGpPWpGaD
Octreotide—SSTR1—Signaling Pathways—AKT1—uterine cancer	2.38e-05	0.000608	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—TP53—uterine cancer	2.31e-05	0.000589	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—HRAS—uterine cancer	2.21e-05	0.000563	CbGpPWpGaD
Octreotide—SSTR5—Signaling Pathways—AKT1—uterine cancer	2.11e-05	0.000539	CbGpPWpGaD
Octreotide—SSTR2—Signaling Pathways—AKT1—uterine cancer	1.95e-05	0.000497	CbGpPWpGaD
